Diabetes

Cell Therapy Trial Success for Type 1 Diabetes

10 Mwezi wa tisa, 2025 Imeripotiwa na AI

In a small cell therapy trial, 10 out of 12 participants with type 1 diabetes no longer required supplemental insulin one year after treatment. This represents a promising advancement in diabetes management.

Higher semaglutide dose boosts weight loss in obesity trials

Two phase 3 clinical trials show that a 7.2 mg weekly dose of semaglutide leads to greater weight loss than the approved 2.4 mg dose in adults with obesity, including those with type 2 diabetes. Nearly half of participants on the higher dose lost 20% or more of their body weight over 72 weeks. The results, published in The Lancet Diabetes & Endocrinology, suggest improved metabolic health with a favorable safety profile.

Study links prediabetes remission to lower diabetes risk without weight loss

8 Mwezi wa kumi, 2025 Imeripotiwa na AI

Researchers in Tübingen have found that people with prediabetes can reduce their risk of developing type 2 diabetes by 71% through lifestyle changes that normalize blood sugar levels, even if they do not lose weight. The study emphasizes the role of improved fat distribution over mere weight reduction. This challenges current guidelines focused primarily on shedding pounds.

WHO Updates Diabetes Essential Medicines

15 Mwezi wa tisa, 2025 Imeripotiwa na AI

The World Health Organization has updated its essential medicines list to include key diabetes treatments, improving access to innovative care. Advancements also feature AI-paired devices and smarter insulin systems for better management. These tools aim to enhance monitoring and delay onset in at-risk groups.

New Advances in Diabetes Management Technologies